Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia

a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network
a medical professional communicates with a patient
Conference Coverage
Patient-Centered Communication Strategies May Improve Tardive Dyskinesia Treatment Uptake
03/22/2026
Maria Mantas
Recent research highlights how targeted communication strategies may improve treatment acceptance in patients with mental illness or tardive dyskinesia (TD).
Recent research highlights how targeted communication strategies may improve treatment acceptance in patients with mental illness or tardive dyskinesia (TD).
Recent research highlights how...
03/22/2026
Psych Congress Network
doctor holds hand of older patient
News
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds
05/21/2025
Maria Mantas
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that...
05/21/2025
Psych Congress Network
poster presentation session at a conference
Conference Coverage
Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds
05/12/2025
Jolynn Tumolo
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed...
05/12/2025
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Jolynn Tumolo
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Clinical Insights
Clinical Pearls to Enhance Tardive Dyskinesia Treatment
01/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia...
01/10/2024
Psych Congress Network
amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Jolynn Tumolo
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network

News

a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network
doctor holds hand of older patient
News
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds
05/21/2025
Maria Mantas
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that...
05/21/2025
Psych Congress Network
poster presentation session at a conference
Conference Coverage
Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds
05/12/2025
Jolynn Tumolo
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed...
05/12/2025
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Jolynn Tumolo
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Jolynn Tumolo
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
News
Valbenazine Use for Tardive Dyskinesia in Older Adults Proves Efficacious
12/08/2021
Heather Flint
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive...
12/08/2021
Psych Congress Network
News
Deutetrabenazine is Beneficial for Long-Term Tardive Dyskinesia Treatment
12/03/2021
Meagan Thistle
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide...
12/03/2021
Psych Congress Network
US FDA sign
News
FDA Approves Oveporexton for Adults With Narcolepsy Type 1
08/06/2026
Brionna Mendoza
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved...
08/06/2026
Psych Congress Network
FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
illustration of a brain
Research Summary
Repeated Low-Dose Oral Esketamine Did Not Increase BDNF in Treatment-Resistant Depression
07/21/2026
Maria Mantas
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving...
07/21/2026
Psych Congress Network
FDA approval stamp
FDA Alerts
FDA Accepts NDA for AXS-12 in Cataplexy Associated With Narcolepsy
07/16/2026
Maria Mantas
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug...
07/16/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
a stethoscope, pills, and brain
Research Summary
Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
07/16/2026
Maria Mantas
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable...
07/16/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network

Quizzes

amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
quiz
Expert Insights Quiz
How does tardive dyskinesia impact medication adherence?
02/14/2023
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with...
02/14/2023
Psych Congress Network
Chepke
Expert Insights Quiz
What is the next step if a patient taking antipsychotics exhibits excessive blink rate?
12/16/2022
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a...
12/16/2022
Psych Congress Network
tardive-dyskinesia-quiz
Quiz
The Impact of Tardive Dyskinesia Across Lifestyle Domains
12/10/2021
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with...
12/10/2021
Psych Congress Network
Quiz
Can long-term anticholinergic medication exposure cause long-term consequences?
10/28/2021
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term...
10/28/2021
Psych Congress Network
Quiz
Antibody Levels in Schizophrenia Patients With Tardive Dyskinesia
10/15/2021
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study,...
10/15/2021
Psych Congress Network
Quiz
Quiz: Are These Antibodies Associated with Orofacial Tardive Dyskinesia?
09/09/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
09/09/2021
Psych Congress Network
Bottles
Quiz
Updated Treatments for Tardive Dyskinesia
08/16/2021
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments...
08/16/2021
Psych Congress Network
quiz
Quiz
Did psychiatrists say they would use anticholinergic medication for TD treatment?
06/17/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
06/17/2021
Psych Congress Network
Quiz
How Often Should Patients Be Evaluated for Tardive Dyskinesia?
05/07/2021
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often...
05/07/2021
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Major Depressive Disorder Insights Quiz
Evaluating Anhedonia in MDD
07/22/2026
Maria Mantas
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of...
07/22/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use